Pfizer (PFE.US) Q2 revenue and profit are both higher than expected, raising full-year EPS outlook.

According to the financial news app Zhtng Cijng, US pharmaceutical giant Pfizer (PFE.US) announced its second quarter financial report on Tuesday. Thanks to strong demand for the heart disease drug Vyndaqel and the anticoagulant drug Eliquis, the company's revenue and profits both exceeded analysts' expectations. In addition, the company also raised its full-year profit forecast. The company's stock price rose more than 3% in pre-market trading, and as of the time of writing, it was up 1.7% in pre-market trading.